Adverse Effects of HMG CoA Reductase Inhibitor and Garlic on Renal Function in Patients with Diabetic Dyslipidemia

被引:0
|
作者
Siddiqui, Naveed Ali [1 ]
Ishaque, Imran [2 ]
Rahat, Yousra [3 ]
Akhtar, Naheed [4 ]
Tehreem, Umaya [3 ]
Javed, Rafia [3 ]
Ali, Rayyan [3 ]
机构
[1] United Med & Dent Coll, Dept Biochem, Karachi, Pakistan
[2] United Med & Dent Coll, Dept Anat, Karachi, Pakistan
[3] United Med & Dent Coll, Karachi, Pakistan
[4] Karachi Inst Med Sceinces, Dept Anat, Karachi, Pakistan
来源
ANNALS ABBASI SHAHEED HOSPITAL & KARACHI MEDICAL & DENTAL COLLEGE | 2021年 / 26卷 / 02期
关键词
Urea; Creatinine; Diabetic dyslipidemia; HMG-CoA reductase inhibitor; Coronary heart disease; CARDIOVASCULAR-DISEASE; FAILURE SECONDARY; LIPID PROFILE; RHABDOMYOLYSIS; SIMVASTATIN;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To analyze the adverse effects of HMG CoA reductase inhibitor (statin) and garlic (Allium sativum) on renal function in diabetic dyslipidemic patients. Methods: This clinical trial was conducted at Surgeon Munawar Memorial Hospital, Karachi from 1st March 2019 to 30th August 2019. Total of 60 patients of 30-70 years of age with abnormal lipid profile were enrolled for this study after a written consent. The study was conducted to assess the side effects of statin (20 mg/day) and garlic (300 mg/day) in diabetic dyslipidemia patients. The study period consisted of six months. Blood pressure, body weight and height of subjects were assessed. The patient answered the questionnaire on health complaints, smoking, social role, drug usage, family history and dietary pattern. The initial inclusion criteria of the patient were 1) Age between 30-70 years old of either sex, 2) Patients with diabetic dyslipidemia. The exclusion criteria were 1) Pregnancy or lactation, 2) Patients with liver diseases, 3) Patients with renal diseases. Detailed medical history and physical examination of all patients were carried out. Results: This study included 60 patients with an abnormal lipid profile of age 30-70 years. International statin product (20 mg/day) and local garlic product (300 mg/day) for 08 weeks were used for oral administration in patients. Urea and creatinine levels in the serum of diabetic dyslipidemic patients were measured before and after treatment with an international statin (20 mg/day) and a local garlic product (300 mg/day). Conclusion: According to the findings of this study, statins increase the serum level of urea and creatinine while has no effect on urea and creatinine serum level.
引用
收藏
页码:71 / 75
页数:5
相关论文
共 50 条
  • [1] Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia
    Isaacsohn, J
    Hunninghake, D
    Schrott, H
    Dujovne, CA
    Knopp, R
    Weiss, SR
    Bays, H
    Crouse, JR
    Davidson, MH
    Keilson, LM
    McKenney, J
    Korenman, SG
    Dobs, AS
    Stein, E
    Krauss, RM
    Maccubbin, D
    Cho, M
    Plotkin, DJ
    Mitchel, YB
    CLINICAL CARDIOLOGY, 2003, 26 (01) : 18 - 24
  • [2] Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection
    Sahu, KM
    Sharma, RK
    Gupta, A
    Gulati, S
    Agarwal, DK
    Kumar, A
    Bhandari, M
    CLINICAL TRANSPLANTATION, 2001, 15 (03) : 173 - 175
  • [3] HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats
    Usui, H
    Shikata, K
    Matsuda, M
    Okada, S
    Ogawa, D
    Yamashita, T
    Hida, K
    Satoh, M
    Wada, J
    Makino, H
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (02) : 265 - 272
  • [4] Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor
    Chapman, BA
    Burt, MJ
    Chisholm, RJ
    Allan, RB
    Yeo, KHJ
    Ross, AG
    DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (02) : 349 - 353
  • [5] Dissolution of Gallstones with Simvastatin, an HMG CoA Reductase Inhibitor
    B. A. Chapman
    M. J. Burt
    R. J. Chisholm
    R. B. Allan
    K. H. J. Yeo
    A. G. Ross
    Digestive Diseases and Sciences, 1998, 43 : 349 - 353
  • [6] Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy
    Yokota, T
    Utsunomiya, K
    Murakawa, Y
    Kurata, H
    Tajima, N
    KIDNEY INTERNATIONAL, 1999, 56 : S178 - S181
  • [7] SIMVASTATIN - A NEW HMG COA REDUCTASE INHIBITOR
    PIETRO, DA
    MANTELL, G
    CARDIOVASCULAR DRUG REVIEWS, 1990, 8 (03): : 220 - 228
  • [8] Pitavastatin: A New HMG-CoA Reductase Inhibitor
    Wensel, Terri M.
    Waldrop, Bruce A.
    Wensel, Brian
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (03) : 507 - 514
  • [9] Pitavastatin: The Newest HMG-CoA Reductase Inhibitor
    Watson, Karol E.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2010, 11 (01) : 28 - 34
  • [10] Geographic Variation in HMG-CoA Reductase Inhibitor Use in Dialysis Patients
    Wetmore, James B.
    Mahnken, Jonathan D.
    Mukhopadhyay, Purna
    Hou, Qingjiang
    Ellerbeck, Edward F.
    Rigler, Sally K.
    Spertus, John A.
    Shireman, Theresa I.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2012, 27 (11) : 1475 - 1483